A Dozen Genes Found Dangerous in Pregnancy A Dozen Genes Found Dangerous in Pregnancy
Conditions linked to the 12 genes included cardiomyopathy, hemorrhage, gestational hypertensive disorders and more.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 25, 2023 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
'I've lived for a year without a PULSE... I run on batteries': Massachusetts woman, 30, with rare genetic condition is being kept alive by mechanical implant as she waits anxiously for a donor to give her a new heart
Sofia Hart, 30, from Massachusetts, has irreversible dilated cardiomyopathy - when one of the ventricles does not work as well, which can lead to heart failure. (Source: the Mail online | Health)
Source: the Mail online | Health - October 25, 2023 Category: Consumer Health News Source Type: news
'I've lived for a year without a PULSE... I run on batteries' Massachusetts woman, 30, with rare genetic condition is being kept alive by mechanical implant as she waits anxiously for a donor to give her a new heart
Sofia Hart, 30, from Massachusetts, has irreversible dilated cardiomyopathy - when one of the ventricles does not work as well, which can lead to heart failure. (Source: the Mail online | Health)
Source: the Mail online | Health - October 24, 2023 Category: Consumer Health News Source Type: news
FDA Denies Approval for Patisiran in ATTR Cardiomyopathy FDA Denies Approval for Patisiran in ATTR Cardiomyopathy
In a complete response letter, the FDA said the clinical meaningfulness of patisiran ' s effects in cardiomyopathy of ATTR amyloidosis are not established, despite good reviews from an advisory panel.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 10, 2023 Category: Internal Medicine Tags: Cardiology News Alert Source Type: news
Episode 11: Peripartum Cardiomyopathy and Pregnancy in Heart Failure Episode 11: Peripartum Cardiomyopathy and Pregnancy in Heart Failure
Drs Michelle M. Kittleson and Kathryn J. Lindley discuss current approaches to treating patients with peripartum cardiomyopathy as well as patients with heart failure who want to become pregnant.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2023 Category: Consumer Health News Tags: Cardiology InDiscussion Source Type: news
FDA Turns Down ATTR Cardiomyopathy Drug
(MedPage Today) -- CLEVELAND -- In a surprise Monday morning move, the FDA declined to expand the indication for anti-amyloid agent patisiran (Onpattro) in treating wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, or cardiac... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - October 9, 2023 Category: American Health Source Type: news
Base Pair Bio Receives Grant from NIH to Help Deliver Therapies for Genetic Heart Disease
Base Pair Biotechnologies, "The Aptamer Discovery Company™" has been recently awarded a grant from NIH entitled, "Aptamer engineering of lentiviral vectors for cardiac gene therapies". HOUSTON, Sept. 27, 2023 /PRNewswire-PRWeb/ -- Hypertrophic cardiomyopathy (HCM) is the leading cause of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 28, 2023 Category: Pharmaceuticals Source Type: news
Patisiran for ATTR Cardiomyopathy Gets FDA Panel Thumbs Up Patisiran for ATTR Cardiomyopathy Gets FDA Panel Thumbs Up
An FDA advisory committee voted 9 to 3 that the benefits of patisiran outweigh the risks for ATTR cardiomyopathy, but many questioned whether the benefit is clinically meaningful.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 14, 2023 Category: Cardiology Tags: Cardiology News Source Type: news
FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy
(MedPage Today) -- FDA advisors conceded on Wednesday that the benefit-risk balance of patisiran (Onpattro) technically checks out in wild-type or hereditary transthyretin amyloid cardiomyopathy (ATTR-CM, also known as cardiac ATTR amyloidosis... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - September 14, 2023 Category: Urology & Nephrology Source Type: news
What Are the Complications of Sickle Cell Trait?
Discussion
Sickle cell disease (SCD) is a group of inherited blood disorders where there are abnormal hemoglobin molecules and the red blood cells take on a characteristic sickled shape instead of a rounded shape. Sickled hemoglobin provides an evolutionary advantage of giving the individual increased protection against severe and cerebral malaria. The sickled shape doesn’t move through the vascular system as well and therefore is more likely to aggregate in small vessels causing an increased risk of vaso-occlusive disease, acute chest syndrome, splenic sequestration, and priapism. There is also an increased risk of ...
Source: PediatricEducation.org - September 4, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
ESC Issues First Comprehensive Cardiomyopathy Guidelines ESC Issues First Comprehensive Cardiomyopathy Guidelines
The European Society of Cardiology has released the first major set of international guidelines to address cardiomyopathies beyond hypertrophic forms.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - September 1, 2023 Category: Internal Medicine Tags: Cardiology News Source Type: news
ESC: Mavacamten Cuts Need for Septal Reduction Tx with Hypertrophic Cardiomyopathy
TUESDAY, Aug. 29, 2023 -- In patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), mavacamten reduces the need for septal reduction therapy (SRT) at week 56, according to a study published online Aug. 28 in JAMA Cardiology to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Novel Amyloid Drug Improves Mid-Term Outcomes in ATTR Cardiomyopathy
(MedPage Today) -- AMSTERDAM -- Novel anti-amyloid agent acoramidis improved a composite of outcome endpoints in the pivotal ATTRibute-CM trial for transthyretin mediated amyloidosis (ATTR) cardiomyopathy, with suggestion of clinical normalization... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - August 29, 2023 Category: Cardiology Source Type: news
Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy Acoramidis Shows Encouraging Results in ATTR Cardiomyopathy
Lead author of the ATTRibute-CM trial says it was"robustly positive," and shows"the tantalizing possibility of genuine clinical improvements" for this progressive and fatal condition.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - August 27, 2023 Category: Neurology Tags: Cardiology News Source Type: news
Viz.ai inks deal with UCSF for three AI algorithms
AI software developer Viz.ai has signed an agreement with the University o...Read more on AuntMinnie.comRelated Reading:
Viz.ai gets FDA nod for cardiomyopathy algorithm
Viz.ai nets FDA nod for AAA detection algorithm
Viz.ai to use recruiting platform for pulmonary embolism trial
Viz.ai inks deal with Bristol Meyers to deploy AI
Viz.ai teams up with Johns Hopkins (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - August 25, 2023 Category: Radiology Source Type: news
